Detalhe da pesquisa
1.
Comparison of Survival and Retention Rates between Infliximab and Adalimumab for Psoriasis: 10-Year Experience at a Single Tertiary Center.
Dermatology
; 239(3): 355-361, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-36871548